EBITDA significantly ahead of expectations Orderbook growth and improved operational delivery lays strong foundations for future growth
EBITDA significantly ahead of expectations Orderbook growth and improved operational delivery lays strong foundations for future growth
€3.2m contract for Venn Life Sciences with global pharmaceutical client
£5.2m RSV human challenge study contract with global biotechnology company in Asia Pacific and Notice of Trading Update
Leeds, UK – December 30, 2022 – 4D pharma plc (AIM: DDDD) (in administration), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived
Cathal Friel’s latest venture, Poolbeg Pharma, a clinical-stage infectious disease firm spun out of Open Orphan, aims to tap into the almost €200 billion infectious disease market.
Phase I results for Imutex’s mosquito vaccine candidate published in leading peer-reviewed journal
Smarttech247, a multi-award-winning provider of AI enhanced cybersecurity services providing automated managed detection and response for a portfolio of international clients, announces that its Ordinary Shares will today be admitted
DeepVerge (AIM: DVRG) announces an organisational restructure of its environmental and life science divisions to meet the growth in demand and maximise the opportunities that lie ahead.
4D pharma’s Blautix® Phase II Clinical Trial Results Published in Alimentary Pharmacology & Therapeutics
Study cohort sizes increase as clients recognise the benefits of human challenge
DeepVerge (AIM: DVRG), announces that further to the announcements of 25 October 2022 and 3 November 2022, Gerard Brandon, Executive Director with responsibility for the Modern Water Division, has resigned